Schizophrenia (SCZ) is one of the most severe and debilitating psychiatric disorders, affecting approximately 1% of the population. SCZ has historically been defined by the presence of psychotic symptoms; however, focus has now turned to cognitive deficits as a significant challenge for individuals with this disorder. Cognitive deficits can include a lack of attention, slower processing speeds, impaired social cognition, and impaired working memory. Current antipsychotics do not improve cognitive functioning. It is known that free phospholipids within the blood, including plasmalogens, are frequently altered in SCZ. Using monophasic lipid extraction and liquid-chromatography-mass-spectrometry (LC-MS), this project attempted to identify an assay of lipids within a control participant’s blood sample. This project also obtained Measurement and Treatment Research to Improve Cognition in SCZ (MATRICS™) Consensus Cognitive Battery (MCCB™) data from 2 control participants. This study also discusses the feasibility of continuing the project in a sample population, as the multiple roadblocks (i.e., multiple changes in laboratories, illnesses, and the onset of coronavirus disease (COVID-19) restrictions, presented to be a significant challenge in recruitment of both participants with SCZ and healthy controls.